Relmada Therapeutics (RLMD) Stock Price, News & Analysis

Company Overview

Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings. In parallel, the company is advancing additional pipeline programs targeting neuropathic pain, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy. Relmada collaborates with academic centers and contract research organizations to conduct multi-center trials across North America and Europe.

Headquartered in New York, Relmada Therapeutics was incorporated in Delaware and maintains its research operations in the United States. The company is led by a management team with extensive experience in biopharmaceutical development, regulatory strategy and commercial planning. Relmada’s common stock is listed on the NASDAQ under the symbol RLMD.

Key Stats

• Today's Range: $4.33 to $4.58
• 50-Day Range: $4.33 to $6.98
• 52-Week Range: $1.13 to $8.00
• Volume: 847,506 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $466.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Relmada Therapeutics Stock Analysis - MarketRank™

Relmada Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 563rd out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Relmada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Relmada Therapeutics has a consensus price target of $12.00, representing about 174.6% upside from its current price of $4.37.

Amount of Analyst Coverage

Relmada Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Relmada Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Relmada Therapeutics is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Relmada Therapeutics is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Relmada Therapeutics has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.14% of the float of Relmada Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Relmada Therapeutics has a short interest ratio ("days to cover") of 9.35.

Change versus previous month

Short interest in Relmada Therapeutics has recently decreased by 4.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Relmada Therapeutics does not currently pay a dividend.

Dividend Growth

Relmada Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.60

News Sentiment

Relmada Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Relmada Therapeutics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for RLMD on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.50% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/03/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RLMD
• CIK: 1553643
• Web: www.relmada.com
• Phone: (786) 629-1376
• Fax: N/A
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Relmada Therapeutics: $12.00
• High Price Target: $19.00
• Low Price Target: $8.00
• Potential Upside/Downside: +174.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.52%
• Return on Assets: -43.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 29.52
• Quick Ratio: 29.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 2.25

Miscellaneous

• Outstanding Shares: 106,670,000
• Free Float: 91,203,000
• Market Cap: $466.15 million
• Optionable: Optionable
• Beta: 0.45